Tazeen Ahmad
BofA Securities, Research Division

[Audio Gap] biotech analyst at the firm. It's my pleasure to have with us our next presenting company, Pharvaris. Up on stage with me are 2 members from Pharvaris. Thanks for making the trip guys. We've got David Nassif, who is Chief Financial Officer; as well as Maggie Beller, who is Head of Corporate and Investor Communications. Thanks, guys, again for flying over from Boston. So maybe we can start off with an overview of the company before we go into some specifics about updating on catalysts.

David Nassif
CFO, Chief Legal Officer & Corporate Secretary

Sure. Well, first of all, thanks for inviting us. We really appreciate it and also the opportunity to have a chat with you. Before we get into the overview, maybe for those of you that don't know, this week, we priced a $132 million underwritten offering, which takes our cash runway into 2028. So now both launches, both ODT and Prophy are fully funded. Any overhang on the stock completely lifted. So we're looking forward to future data and approvals. As to the pipeline, I guess there are basically 3 updates.

On ODT, we are on track for the first half of 2026 filing of the NDA on -- as it pertains to prophy, we are still on track for top line readout by Q3 2026. And then on AAE, the enrollment is progressing well. So if you wanted to talk about differentiation of the products, basically, our story is we are a portfolio strategy at this point, where patients, payers professionals know they can use our products